Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (158)

« Back to Publications

Assessing clinical and cost effectiveness of total versus partial knee replacement (TOPKAT): 10-year follow-up of a multicentre, randomised controlled trial.

Beard DJ. et al, (2026), Lancet Rheumatol, 8, e116 - e126

Association between non-invasive biomarkers and quality of life in Primary Sclerosing Cholangitis

Dai J. et al, (2025), Plos One, 20

Real-world waitlist randomised controlled trial of gameChange VR to treat severe agoraphobic avoidance in patients with psychosis: A study protocol

Freeman D. et al, (2025), BMJ Open, 15

Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial

Zhou J. et al, (2025), Eclinicalmedicine, 85

Efficacy of a 6-month supported online programme (Feeling Safer) for the treatment of persecutory delusions: protocol for a randomised controlled trial

Freeman D. et al, (2025), BMJ Open, 15

Using QALYs as an Outcome for Assessing Global Prediction Accuracy in Diabetes Simulation Models

Dakin HA. et al, (2025), Medical Decision Making, 45, 45 - 59

Assessing clinical and cost effectiveness of total versus partial knee replacement (TOPKAT): 10-year follow-up of a multicentre, randomised controlled trial

Beard DJ. et al, (2025), Lancet Rheumatology

The Impact of Unrelated Future Medical Costs on Economic Evaluation Outcomes for Different Models of Diabetes

Zhao T. et al, (2024), Applied Health Economics and Health Policy, 22, 861 - 869

Examining the Impact of Structural Uncertainty Across 10 Type 2 Diabetes Models: Results From the 2022 Mount Hood Challenge

Altunkaya J. et al, (2024), Value in Health, 27, 1338 - 1347

Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management

Gao N. et al, (2024), PharmacoEconomics, 42, 1017 - 1028

The economic burden of cancer, coronary heart disease, dementia, and stroke in England in 2018, with projection to 2050: an evaluation of two cohort studies

Landeiro F. et al, (2024), The Lancet Healthy Longevity, 5, e514 - e523

Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91)

Adler AI. et al, (2024), The Lancet, 404, 145 - 155

Trajectories of clinical characteristics, complications and treatment choices in data-driven subgroups of type 2 diabetes

Li X. et al, (2024), Diabetologia, 67, 1343 - 1355

Associations between BMI and hospital resource use in patients hospitalised for COVID-19 in England: a community-based cohort study

Altunkaya J. et al, (2024), Lancet Diabetes and Endocrinology, 12, 462 - 471

Health-related quality of life and healthcare costs of symptoms and cardiovascular disease events in patients with atrial fibrillation: a longitudinal analysis of 27 countries from the EURObservational Research Programme on Atrial Fibrillation general long-term registry

Walli-Attaei M. et al, (2024), Europace, 26

Load More

1
2
3
4
5
6
7
...
»